The Safety and Early Efficacy of Oral-Loaded Divalproex Versus Standard-Titration Divalproex, Lithium, Olanzapine, and Placebo in the Treatment of Acute Mania Associated With Bipolar Disorder

University of Texas Medical Branch at Galveston, Galveston, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.5). 08/2003; 64(7):841-6. DOI: 10.4088/JCP.v64n0717
Source: PubMed


Previous studies have examined the safety and tolerability of oral-loaded divalproex sodium in the treatment of acute mania, but not the early efficacy of this dosing strategy. The purpose of this study was to evaluate the early efficacy of oral-loaded divalproex.
In this pooled analysis, 348 subjects from 3 randomized, double-blind, parallel-group, active- or placebo-controlled studies were used to compare the efficacy, safety, and tolerability of oral-loaded divalproex with standard-titration divalproex, lithium, olanzapine, or placebo. Subjects were inpatients diagnosed with acute mania associated with bipolar I disorder (DSM-III-R or -IV and SADS-Change Version). Patients were administered oral-loaded divalproex (20 or 30 mg/kg/day on days 1 and 2 followed by 20 mg/kg/day, and increased at physician's discretion), standard-titration divalproex initiated at 250 mg t.i.d. and titrated to 40-150 microg/mL, lithium (300 mg t.i.d. initial dose) titrated to 0.4 to 1.5 mEq/L, olanzapine (10 mg q.d. initial dose) up to 20 mg/day, or placebo.
The results demonstrate an early efficacy advantage for oral-loaded divalproex compared to standard-titration divalproex at days 5, 7/8, and 10. Efficacy was improved over lithium on day 7/8. There were no efficacy differences between divalproex loading and olanzapine. Divalproex loading showed greater efficacy than placebo at all time points. Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters.
These results suggest the oral loading of divalproex leads to a more rapid antimanic effect when compared with standard-titration divalproex, lithium, or placebo and is better tolerated than olanzapine and as well tolerated as lithium or standard-titration divalproex.

14 Reads
    • "This pattern is similar to a study from the USA.[7] This may be due to the fact that valproate is considered to be rapidly effective in the management of acute mania.[22] Furthermore, valproate may have been preferred over lithium because of the fact that valproate is usually started after the basic investigations like liver function test and hemogram, in contrast to lithium where one requires more extensive investigations, which may not be at times feasible in acutely disturbed patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although almost all psychotropic medications available worldwide are readily available in India, there is meager data in this country on the prescription patterns of psychiatrists. To study the first prescription handed over to patients attending the psychiatry outpatient clinic of a tertiary care hospital. Data of all patients (for the period of January 1, 2009 to November 30, 2010; diagnosed with an ICD-10 diagnosis of F2-F4) were extracted from the computer-based registry and analyzed. Ten thousand two hundred and fourteen (10 214) patients were diagnosed to have a diagnosis of F2-F4 ICD-10 category. In all diagnostic groups, olanzapine was the most commonly prescribed antipsychotic followed by risperidone. Very few patients (8%) received typical antipsychotic medication. In all diagnostic groups, escitalopram was the most commonly prescribed antidepressant; other frequently prescribed antidepressants were sertraline, paroxetine, and venlafaxine. Among the mood stabilizers, valproate was preferred over lithium. In all the groups, more than half of the patients were prescribed benzodiazepines, clonazepam being the most commonly prescribed agent, followed by lorazepam. The mean number of psychotropic medications was highest in the bipolar disorder group. Very few patients received the combination of same group of drugs. Olanzapine, escitalopram, and clonazepam are the most commonly prescribed antipsychotic, antidepressants, and benzodiazepines, respectively. Valproate was preferred over lithium as a mood stabilizer. In general, the prescription trends were in accordance to the recommendations of various treatment guidelines, except for the use of benzodiazepines, which was higher.
    Indian Journal of Pharmacology 05/2012; 44(3):319-25. DOI:10.4103/0253-7613.96302 · 0.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder is a less common biologic disorder in primary care than are depressive and anxiety disorders, but there is a high risk for poor outcomes for patients. Primary care physicians (PCPs) are assuming increasing responsibility for the care of these patients in today's man-aged care environment, working independently or in collaboration with a psychiatrist. The PCP needs to carefully assess patients presenting with depression, since many are bipolar. The PCP must then skillfully man-age these patients because of the significant morbidity and mortality associated with the disorder. This article outlines a diagnostic approach for patients in primary care practice who present with mood symptoms. The article also presents a management strategy for those who are diagnosed with bipolar disorder, including patients who are considering pregnancy or who are pregnant.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess new treatment options for bipolar disorders. Controlled studies of new treatments for bipolar disorders were identified by computerized searches and reviews of scientific meeting proceedings, and were compiled by drug category. Two main categories of medications, newer anticonvulsants and newer antipsychotics, are yielding emerging new treatment options for bipolar disorders. Newer anticonvulsants have diverse psychotropic profiles, and although not generally effective for acute mania, may have utility for other aspects of bipolar disorders (e.g. lamotrigine for maintenance or acute bipolar depression), or for comorbid conditions (e.g. gabapentin for anxiety or pain, topiramate for obesity, bulimia, alcohol dependence, or migraine, and zonisamide for obesity). In contrast, newer antipsychotics generally appear effective for acute mania, and some may ultimately prove effective in acute depression (e.g. olanzapine combined with fluoxetine, quetiapine) and maintenance (e.g. olanzapine). Emerging research is yielding new treatment options for bipolar disorders and comorbid conditions.
    Acta psychiatrica Scandinavica. Supplementum 02/2004; 422(422):18-33. DOI:10.1111/j.1600-0447.2004.00410.x
Show more